The drugmaker is working toward getting the vaccine fully approved by the FDA rather than just an emergency use authorization, The Hill reported. It’s also working on second-phase testing for its vaccine in people ages 12 to 17.
Moderna CEO Stéphane Bancel told CNBC April 13 he hopes to have booster shots to target emerging virus variants available by the fall.
“The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our COVID-19 vaccine as necessary until the pandemic is under control,” Mr. Bancel said in a news release.
He also told CNBC he hopes Moderna will eventually be able to make two-in-one vaccines protecting against both the seasonal flu and COVID-19.
More articles on pharmacy:
How Walgreens, CVS, states are handling the J&J vaccine pause
6 most reputable drugmakers
Biden: J&J pause won’t affect US vaccination pace
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
